Published in Mol Pharmacol on November 10, 2016
ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem (2001) 8.78
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol (2011) 2.66
Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem (1982) 2.48
Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer (2005) 2.30
Myeloperoxidase: a target for new drug development? Br J Pharmacol (2007) 2.09
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood (2010) 1.96
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A (2007) 1.92
Eukaryotic DNA topoisomerase II beta. Bioessays (1998) 1.83
International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer (2002) 1.48
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med (2008) 1.31
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci U S A (2012) 1.29
Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol (1998) 1.26
Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr (2000) 1.23
Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res (2000) 1.19
Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact (2009) 1.19
Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry (2001) 1.16
Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res (2001) 1.15
Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons. J Biol Chem (1995) 1.14
2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem (2011) 1.01
Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clin Biochem (2010) 1.00
Human neutrophils employ myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry (1998) 0.99
Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res (1987) 0.99
Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int J Environ Res Public Health (2012) 0.97
Myeloperoxidase expression in CD34+ normal human hematopoietic cells. Blood (1993) 0.94
Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos (2004) 0.93
Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress. Anticancer Drugs (1997) 0.89
Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR Study. Biochemistry (1989) 0.89
Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol (2006) 0.88
MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA. Biol Open (2012) 0.88
Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun (1986) 0.86
Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates. J Biol Chem (2013) 0.86
The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol (1998) 0.86
The post-translational processing of myeloperoxidase is regulated by the availability of heme. Arch Biochem Biophys (1994) 0.85
Etoposide quinone is a redox-dependent topoisomerase II poison. Biochemistry (2011) 0.84
Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide. J Nucleic Acids (2010) 0.84
Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res (1993) 0.83
An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay. Mutagenesis (2010) 0.83
Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. Clin Cancer Res (2004) 0.82
Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin. Nucleus (2011) 0.82
Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. J Med Chem (2013) 0.82
Etoposide quinone is a covalent poison of human topoisomerase IIβ. Biochemistry (2014) 0.80
Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res (1999) 0.80
Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Anticancer Drug Des (1995) 0.80
Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells. Mol Pharmacol (2010) 0.80
Mitoxantrone, More than Just Another Topoisomerase II Poison. Med Res Rev (2015) 0.80
Myeloperoxidase: expression and modulation in a large panel of human leukemia-lymphoma cell lines. Blood (1993) 0.78
The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1. Genes Chromosomes Cancer (2013) 0.78
Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors. Curr Med Chem (2016) 0.78
Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase. ACS Med Chem Lett (2015) 0.78
Reduction of phenoxyl radicals of the antitumour agent etoposide (VP-16) by glutathione and protein sulfhydryls in human leukaemia cells: Implications for cytotoxicity. Toxicol In Vitro (1996) 0.77
Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II. Biochem Pharmacol (2016) 0.77
PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J Pharmacol Exp Ther (2015) 0.77
Neutrophil-mediated activation of mitoxantrone to metabolites which form adducts with DNA. Cancer Lett (1997) 0.76